Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2003
NET PRODUCT SALES DETAIL
----------------------------------------------------------------
2Q `03 vs. 2Q `02
----------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
- ------------------------------------
PRODUCT % CHG $ % CHG $ % CHG $
- ----------------------------------------------------------------------------------------------------
AGGRASTAT -9% 26 -49% 6 22% 19
- ----------------------------------------------------------------------------------------------------
ARCOXIA * 16 N/M - * 16
- ----------------------------------------------------------------------------------------------------
CANCIDAS * 62 * 36 * 26
- ----------------------------------------------------------------------------------------------------
COZAAR / HYZAAR 3% 543 -33% 149 28% 394
- ----------------------------------------------------------------------------------------------------
CRIXIVAN/STOCRIN 0% 82 -25% 25 18% 57
- ----------------------------------------------------------------------------------------------------
EMEND * 15 * 15 N/M -
- ----------------------------------------------------------------------------------------------------
FOSAMAX -9% 535 -40% 251 71% 284
- ----------------------------------------------------------------------------------------------------
INVANZ * 8 * 7 * 2
- ----------------------------------------------------------------------------------------------------
MAXALT -7% 52 -28% 27 39% 24
- ----------------------------------------------------------------------------------------------------
PRIMAXIN 3% 146 -29% 33 18% 113
- ----------------------------------------------------------------------------------------------------
PRINIVIL / PRINZIDE -80% 38 -88% 21 -5% 17
- ----------------------------------------------------------------------------------------------------
PROPECIA -3% 51 -17% 21 11% 30
- ----------------------------------------------------------------------------------------------------
PROSCAR 53% 174 83% 87 32% 88
- ----------------------------------------------------------------------------------------------------
SINGULAIR 89% 427 * 272 59% 156
- ----------------------------------------------------------------------------------------------------
TIMOPTIC/TIMOPTIC XE -1% 43 -18% 5 2% 37
- ----------------------------------------------------------------------------------------------------
TRUSOPT/COSOPT 8% 123 -8% 52 23% 72
- ----------------------------------------------------------------------------------------------------
VASOTEC / VASERETIC -2% 201 50% (4) -4% 205
- ----------------------------------------------------------------------------------------------------
VIOXX 1% 801 -7% 543 24% 258
- ----------------------------------------------------------------------------------------------------
ZOCOR 3% 1,242 18% 773 -14% 468
- ----------------------------------------------------------------------------------------------------
HEPATITIS VACCINES -18% 52 -25% 43 38% 9
- ----------------------------------------------------------------------------------------------------
VIRAL VACCINES -31% 134 -35% 125 * 10
- ----------------------------------------------------------------------------------------------------
OTHER VACCINES -19% 50 -21% 39 -11% 11
- ----------------------------------------------------------------------------------------------------
* > 100%
N/M - Not Meaningful
TOTAL SALES: VOLUME, PRICE, EXCHANGE
----------------------------------------------------
2Q `03 % CHG. VOL PX FX
- ----------------------------------------------------------------------------------------
TOTAL SALES $13,281 4% -4 6 2
------- -- --- -- --
Total Pharmaceutical Sales 5,546 7% 2 0 5
------- -- --- -- --
U.S. 3,235 2% 1 1 0
Foreign 2,312 14% 2 -1 13
------------------------------
Other Medco Sales 7,735 2%
- ----------------------------------------------------------
Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SIX MONTHS YEAR TO DATE
2003
NET PRODUCT SALES DETAIL
------------------------------------------------------------------
JUNE YTD `03 vs. JUNE YTD `02
------------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
- ----------------------------------
PRODUCT % CHG $ % CHG $ % CHG $
- ----------------------------------------------------------------------------------------------------
AGGRASTAT -6% 48 -58% 9 33% 39
- ----------------------------------------------------------------------------------------------------
ARCOXIA * 28 N/M - * 28
- ----------------------------------------------------------------------------------------------------
CANCIDAS * 108 * 62 * 46
- ----------------------------------------------------------------------------------------------------
COZAAR / HYZAAR 24% 1,187 9% 446 36% 741
- ----------------------------------------------------------------------------------------------------
CRIXIVAN/STOCRIN 11% 166 17% 64 8% 102
- ----------------------------------------------------------------------------------------------------
EMEND * 15 * 15 N/M -
- ----------------------------------------------------------------------------------------------------
FOSAMAX 23% 1,348 4% 836 72% 512
- ----------------------------------------------------------------------------------------------------
INVANZ * 14 * 11 * 3
- ----------------------------------------------------------------------------------------------------
MAXALT 5% 131 -5% 87 33% 44
- ----------------------------------------------------------------------------------------------------
PRIMAXIN 18% 309 31% 94 13% 215
- ----------------------------------------------------------------------------------------------------
PRINIVIL / PRINZIDE -81% 74 -88% 43 -13% 31
- ----------------------------------------------------------------------------------------------------
PROPECIA 16% 117 21% 58 12% 59
- ----------------------------------------------------------------------------------------------------
PROSCAR 36% 313 54% 151 23% 162
- ----------------------------------------------------------------------------------------------------
SINGULAIR 40% 901 34% 613 54% 288
- ----------------------------------------------------------------------------------------------------
TIMOPTIC/TIMOPTIC XE -3% 79 -44% 7 4% 71
- ----------------------------------------------------------------------------------------------------
TRUSOPT/COSOPT 15% 230 10% 98 19% 133
- ----------------------------------------------------------------------------------------------------
VASOTEC / VASERETIC -6% 369 * (8) -2% 377
- ----------------------------------------------------------------------------------------------------
VIOXX -4% 1,328 -15% 861 22% 467
- ----------------------------------------------------------------------------------------------------
ZOCOR 5% 2,491 11% 1,486 -2% 1,005
- ----------------------------------------------------------------------------------------------------
HEPATITIS VACCINES 13% 117 6% 98 69% 20
- ----------------------------------------------------------------------------------------------------
VIRAL VACCINES -11% 252 -15% 234 * 18
- ----------------------------------------------------------------------------------------------------
OTHER VACCINES 22% 109 21% 85 25% 24
- ----------------------------------------------------------------------------------------------------
* > 100%
N/M - Not Meaningful
TOTAL SALES: VOLUME, PRICE, EXCHANGE
-------------------------------------------------
YTD `03 % CHG. VOL PX FX
- -----------------------------------------------------------------------------------
TOTAL SALES $26,670 7% -2 7 2
------- --- --- -- --
Total Pharmaceutical Sales 11,263 12% 6 1 5
------- --- --- -- --
U.S. 6,823 8% 6 2 0
Foreign 4,440 18% 7 -1 12
--------------------------
Other Medco Sales 15,407 3%
- ---------------------------------------------------------
Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SECOND QUARTER
2003
================================================================================
OTHER (INCOME)/EXPENSE, NET
---------------------------------------------------
2Q `03 2Q `02 YTD 2003 YTD 2002
-------------------------------------------------------------------------------------------------
INTEREST INCOME $ (82.6) $ (105.5) $ (170.9) $ (203.9)
INTEREST EXPENSE 94.6 97.5 189.9 192.8
EXCHANGE (GAINS)/LOSSES (16.3) 5.3 (23.4) 2.6
MINORITY INTERESTS 40.6 59.9 92.4 110.6
AMORTIZATION OF INTANGIBLES 60.5 51.0 115.3 102.4
Other, net (195.4) (10.9) (242.6) (63.3)
---------------------------------------------------
TOTAL $ (98.6) $ 97.3 $ (39.3) $ 141.2
-------------------------------------------------------------------------------------------------
================================================================================
JOINT VENTURE SALES DETAIL
All sales reported here are end-market JV sales, presented on a "NET" basis.
---------------------------------------------------
MERIAL 2Q `03 2Q `02 YTD 2003 YTD 2002
-------------------------------------------------------------------------------------------------
IVOMEC, HEARTGARD, other avermectins $ 114 $ 121 $ 211 $ 220
FRONTLINE 170 142 302 262
Biologicals 98 97 200 184
Other Animal Health 50 47 96 92
Poultry Genetics 21 41 76 78
---------------------------------------------------
TOTAL MERIAL SALES $ 453 $ 448 $ 885 $ 836
-------------------------------------------------------------------------------------------------
---------------------------------------------------
AVENTIS PASTEUR-MSD 2Q `03 2Q `02 YTD 2003 YTD 2002
-------------------------------------------------------------------------------------------------
HEPATITIS VACCINES $ 19 $ 17 $ 37 $ 30
VIRAL VACCINES 13 9 24 16
Other Vaccines 114 81 204 150
---------------------------------------------------
TOTAL AP-MSD SALES $ 146 $ 107 $ 265 $ 196
-------------------------------------------------------------------------------------------------
---------------------------------------------------
MERCK / SCHERING-PLOUGH COLLABORATION 2Q `03 2Q `02 YTD 2003 YTD 2002
-------------------------------------------------------------------------------------------------
Zetia (Worldwide) $ 123 $ - $ 169 $ -
TOTAL $ 123 $ - $ 169 $ -
-------------------------------------------------------------------------------------------------
================================================================================
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS)
--------------------------------------
2003 MAIL RETAIL TOTAL
------------------------------------------------------------------------------------
FIRST QUARTER 20 113 133
SECOND QUARTER 19 112 131
--------------------------------------
YEAR TO DATE 39 226 265
------------------------------------------------------------------------------------
--------------------------------------
2002 MAIL RETAIL TOTAL
------------------------------------------------------------------------------------
FIRST QUARTER 20 121 141
SECOND QUARTER 21 119 140
--------------------------------------
YEAR TO DATE 41 239 280
------------------------------------------------------------------------------------